OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Britain Courts Anthropic Amid US Defense Department Dispute 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
NEW YORK, Jan. 27, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased TG Therapeutics, Inc. (NASDAQ:TGTX) securities between September 15, 2014 and October 12, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/tg-therapeutics-inc. There is no cost or obligation to you.
The complaint alleges that, throughout the Class Period, TGTX misrepresented and/or omitted material information concerning its GENUINE Phase III clinical trial for its proprietary combination of drug therapies TG-1101 and TGR-1202. The Phase III trial consisted of two parts, Part I evaluating the effect of the addition of TG-1101 to ibrutinib on overall response rate (ORR) in approximately 200 patients, and Part II evaluating the effect of the addition of TG-1101 to ibrutinib on progression-free survival (PFS) in all study patients. During the class period TGTX repeatedly assured investors as to the efficacy and potential FDA approval of the treatment, referring to it as a “best-in-class treatment.” Then on October 13, 2016, TGTX announced that it would abandon Part II of the study, thus annulling its filed Special Protocol Assessment with the FDA and cutting enrollment and increasing the likelihood that the FDA would not approve the combination treatment.
If you suffered a loss in TG Therapeutics you have until March 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/tg-therapeutics-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
